Verition Fund Management
ARQT icon

Verition Fund Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Verition Fund Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,482
Closed -$217K – 2300
2025
Q4 		$217K Sell
7,482
-29,012
-79% -$743K ﹤0.01% 3144
2025
Q3 		$688K Sell
36,494
-19,606
-35% -$309K ﹤0.01% 2821
2025
Q2 		$787K Buy
+56,100
New +$786K ﹤0.01% 2642
2025
Q1 		– Sell
-20,023
Closed -$279K – 3314
2024
Q4 		$279K Buy
+20,023
New +$219K ﹤0.01% 2811

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Verition Fund Management's ARQT Position: Q1 2026 in Review

Verition Fund Management sold out of Arcutis Biotherapeutics (ARQT) in Q1 2026, closing a stake of 7,482 shares — an estimated $217K sold.

Verition Fund Management first reported a position in ARQT in Q4 2024 and held it in 4 quarters. The position peaked at $787K in Q2 2025. 270 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Verition Fund Management reported no remaining Arcutis Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 7,482 Arcutis Biotherapeutics shares in Q1 2026, an estimated $217K.
  • Verition Fund Management first reported a position in Arcutis Biotherapeutics in Q4 2024 and held it in 4 quarters.
  • Verition Fund Management's Arcutis Biotherapeutics position peaked at $787K in Q2 2025.
  • 270 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.